AstraZeneca (NYSE:AZN) announces positive results from two Phase 3 clinical trials, OLYMPUS and ROCKIES, evaluating roxadustat in chronic kidney disease patients with anemia who are either dialysis-dependent (ROCKIES) or not (OLYMPUS).
Both studies met the primary endpoints. The data will support marketing applications in the U.S. and other major markets.
Detailed results will be submitted for presentation at future medical conferences.
Shares are up 3% premarket on light volume.
Related ticker: (NASDAQ:FGEN)
Subscribe for full text news in your inbox